Veeva’s latest report, The State of Data, Analytics, and AI in Commercial Biopharma, revealed a critical industry paradox: ...

The Autumn Budget, with its £26 billion tax rise by 2029-30, will “drive an exodus of wealth from Britain,” warned Nigel ...

Digital health and digital therapeutics have been around for a long time now. But when will we really start to realise the ...

Novo Nordisk is filing its supplemental new drug application (sNDA) for Wegovy 7.2 mg on the back of the phase 3b STEP UP ...

Sanofi is being probed for 'money laundering of tax fraud', 'money laundering of tax fraud by an organised or aggravated group', and 'criminal conspiracy', according to the newspaper.

Kelonia Therapeutics only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but already has ...

Prenuvo CEO Andrew Lacy sat down with pharmaphorum after their Frontiers Health keynote to discuss: ...

Anti-APRIL antibody Voyxact (sibeprenlimab) has been approved by the US regulator to reduce proteinuria in adults with ...

A regimen based on Jazz Pharma and PharmaMar's Zepzelca and Roche's Tecentriq has been approved in the US as a maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). The approval ...

AstraZeneca's immunotherapy Imfinzi is the first drug therapy to be recommended for routine NHS use as a treatment for limited-stage small cell lung cancer (LS-SCLC), a particularly hard-to-treat ...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform. Genentech is providing ...

The list of new medicines recommended for approval at the October meeting of the EMA's human medicines committee includes Brinsupri, the first treatment for serious chronic lung disease non-cystic ...